We recently reported RBL2-DREAM-mediated repression of aurora kinase (AURK) pathway genes improves therapy responses in p53 wild-type (WT) non-small cell lung cancer (NSCLC) cells, and loss of this repression correlates with poor outcomes specifically in patients whose tumors express WT p5310. The gene discussed is RBL2; the disease is non-small cell lung carcinoma.